Symptomatic pharmacotherapy of migraine

Clinical Therapeutics

Volumn 21, Issue 7, 1999, Pages 1118-1130

  Lobo, Bob L ^a   Cooke, Stephen C ^b   Landy, Stephen H ^c  

^a Methodist Healthcare   (United States)

^b Memphis Mental Health Institute   (United States)

^c Wesley Headache Clinic   (United States)

Author keywords

Ergot alkaloids; Migraine headache; Serotonin agonists; Triptans

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIEMETIC AGENT; ANTIMIGRAINE AGENT; BUTALBITAL; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; BUTORPHANOL; CAFFEINE; CHLORPROMAZINE; CORTICOSTEROID; DEXAMETHASONE; DICHLORALPHENAZONE; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOT ALKALOID; ERGOT DERIVATIVE; EXCEDRIN; HYDROXYZINE; ISOMETHEPTENE; ISOMETHEPTENE MUCATE; KETOROLAC; METOCLOPRAMIDE; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PETHIDINE; PROCHLORPERAZINE; PROMETHAZINE; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

ADVERSE DRUG REACTION; DRUG CONTRAINDICATION; DRUG INDICATION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIGRAINE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RECTAL DRUG ADMINISTRATION; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SYMPTOMATOLOGY; TREATMENT PLANNING;

EID: 0032810476     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)80017-X     Document Type: Article

References (48)

1. 1. Lipton RB, Stewart WF, von Korff M. Burden of migraine: Societal costs and therapeutic opportunities. Neurology. 1997;48(Suppl 3):S4-S9 .
2. 2. Rapoport AM, Adelman JU. Cost of migraine management: A pharmacoeconomic overview. Am J Managed Care. 1998;4:531-545.
3. 3. Osterhaus JT, Gutterman DL, Plachetka JR. Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics. 1992;2:67-76.
4. 4. Lipton RB, Stewart WF. Migraine in the United States: A review of epidemiology and health care use. Neurology. 1993; 43(Suppl 3):S6-S10.
5. 5. Dalessio DJ. Diagnosing the severe headache. Neurology. 1994:44(Suppl 3): S6-S12.
6. 6. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. Neurology. 1994;44(Suppl 7):S6-S16.
7. 7. Saper JR. Diagnosis and symptomatic treatment of migraine. Headache. 1997; 37(Suppl 1):S1-S14.
8. 8. Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clin Proc. 1996;71:1055-1066.
9. 9. Ferrari MD. Migraine. Lancet. 1998;351: 1043-1051.
10. 10. Welch KMA. Drug therapy of migraine. NEJM. 1993;329:1476-1484.
11. 11. Van Der Kamp W, Massen Van En Brink A, Ferrari MD, Van Dijk JG. Interictal cortical hyperexcitability in migraine patients demonstrated with transcranial magnetic stimulation. J Neurol Sci. 1996;139:106-110.
12. 12. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci. 1992;13:307-312.
13. 13. Sheftell FD. Role and impact of over-the-counter medications in the management of headache. Neurol Clin. 1997;15:187-197.
14. 14. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol. 1990;30:405-409.
15. 15. Volans GN. The effect of metoclopramide on the absorption of effervescent aspirin in migraine. Br J Clin Pharmacol. 1975; 2:57-63.
16. 16. Lipton RB, Stewart WF, Ryan RE, et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998;55:210-217.
17. 17. Shrestha M, Singh R, Moreden J, Hayes JE. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura: A prospective, randomized, double-blind trial. Arch Intern Med. 1996;156:1725-1728.
18. 18. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med. 1989;18:360-365.
19. 19. Jones S, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA. 1989;261:1174-1176.
20. 20. Jones EB, Gonzalez ER, Boggs JG, et al. Safety and efficacy of rectal prochlorperazine for the treatment of migraine in the emergency department. Ann Emerg Med. 1994;24:237-241.
21. 21. Ellis GL, Delaney J, DeHart DA, Owens A. The efficacy of metoclopramide in the treatment of migraine headache. Ann Emerg Med. 1993;22:191-195.
22. 22. Coppola M, Yealy DM, Leibold RA. Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. Ann Emerg Med. 1995;26:541-546.
23. 23. Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37(Suppl 1):S15-S25.
24. 24. Young WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: Current perspectives. Headache. 1997;37(Suppl 1): S42-S45.
25. 25. Rapoport AM, Silberstein SD. Emergency treatment of headache. Neurology. 1992; 42(Suppl 2):43-44.
26. 26. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996;53:180-184.
27. 27. Touchon J, Bertin L, Pilgrim AJ, et al. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology. 1996;47:361-365.
28. 28. Gallagher RM. Acute treatment of migraine with dihydroergotamine nasal spray. Arch Neurol. 1996;53:1285-1291.
29. 29. Bateman DN. Sumatriptan. Lancet. 1993; 341:221-224.
30. 1D) agonists and other agents in acute migraine. Neurol Clin. 1997;15:61-83.
31. 31. Perry CM, Markham A. Sumatriptan: An updated review of its use in migraine. Drugs. 1998;55:889-922.
32. 32. Pfaffenrath V, Cunin G, Sjonell G, Prendergast S. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: Defining the optimum doses of oral sumatriptan. Headache. 1998;38:184-190.
33. 33. Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet. 1995;346:923-926.
34. 34. Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine: Results of two clinical studies. Neurology. 1997;49:1225-1230.
35. 1B/1D receptor agonists. Neurology. 1997;48(Suppl 3):S21-S24.
36. 36. Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan for the acute treatment of migraine: A multicenter, double-blind, placebo-controlled, dose range-finding study. Neurology. 1997;49:1210-1218.
37. 37. Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg of zolmitriptan for the acute treatment of migraine. Neurology. 1997;49:1219-1225.
38. 38. Zeneca's Zomig produces migraine relief in 54% and 89% of patients with poor response to Imitrex. Zomig will be launched in January. F-D-C Reports, Pharmaceutical Approvals Monthly. 1998;3-6.
39. 1 receptor agonist for acute treatment of migraine. Formulary. 1998;33: 521-533.
40. 40. Klassen A, Elkind A, Asgharnejad M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache. 1997;37:640-645.
41. 41. Dahlof C, Winter P, Whitehouse H, Hassani H. Randomized, double-blind, placebo-controlled comparison of oral naratriptan and oral sumatriptan in the acute treatment of migraine. Neurology. 1997; 48:A85. Abstract S08.003.
42. 42. Maxalt prescribing information. West Point, Pa: Merck & Co., Inc.; 1998.
43. 43. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (Maxalt) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache. 1998;38:281-287.
44. 44. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Headache. 1998;38:737-747.
45. 45. Ziegler DK. Opioids in headache treatment: Is there a role? Neurol Clin. 1997; 15:199-207.
46. 46. Carleton SC, Shesser RF, Pietrak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med. 1998;32:129-138.
47. 47. Mathew NT. Transformed migraine, analgesic rebound, and other chronic daily headaches. Neurol Clin. 1997;15:167-185.
48. 48. Markley HG. Chronic headache: Appropriate use of opiate analgesics. Neurology. 1994;44(Suppl 3):S18-S24.